Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim in Chinese Subjects With Immune Thrombocytopenia: A Phase I/II Trial

Junyuan Qi, Li Zheng, Bei Hu, Hu Zhou, Qing He, Hong Liu, Hironori Kawai, Renchi Yang, Junyuan Qi, Li Zheng, Bei Hu, Hu Zhou, Qing He, Hong Liu, Hironori Kawai, Renchi Yang

Abstract

Romiplostim is approved for the treatment of immune thrombocytopenia (ITP). This study aimed to evaluate the pharmacokinetics, safety, and pharmacodynamics of romiplostim in Chinese patients with ITP. This multicenter, open-label, dose-escalation phase I/II trial enrolled ITP patients from 5 centers in China between October 2015 and August 2017. There were 2 cohorts: 1 μg/kg and 3 μg/kg weekly for 2 weeks. The end points included pharmacokinetics, platelet changes from baseline, hematological indicators, and adverse events (AEs). Sixteen participants, with 8 patients in each cohort, were enrolled. In the 1 μg/kg cohort, time to maximum concentration was 4.00 (4.00-7.83) hours, maximum serum drug concentration was 52.0 (16.0-228.0) pg/mL, and area under the serum drug concentration-time curve from time 0 to the last detectable time point was 389 (32.0-5400) pg · h/mL. In the 3 μg/kg cohort, time to maximum serum drug concentration was 11.91 (4.00-12.00) hours, maximum serum drug concentration was 105.0 (25.5-313.0) pg/mL, and half-life was 12.7 (8.2-23.6) hours. The absolute change of peak platelet count from baseline was 14 (3-40) and 72 (3-369) ×109 /L in the 1 and 3 μg/kg cohorts, respectively. Seven (87.5%) and eight (100%) participants had treatment-emergent AEs in 1 μg/kg cohort and 3 μg/kg cohort, respectively. No major AEs occurred in the 2 cohorts. Romiplostim (1 and 3 μg/kg) is safe and well tolerated in Chinese patients with ITP.

Trial registration: ClinicalTrials.gov NCT02868060.

Keywords: immune thrombocytopenia; pharmacodynamics; pharmacokinetics; phase I/II; romiplostim; safety.

Conflict of interest statement

All authors declare that they have no competing interests.

© 2021 The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.

Figures

Figure 1
Figure 1
Pharmacokinetics of romiplostim. Mean serum romiplostim concentration (pg/mL), linear plot. The error bars are standard deviations.
Figure 2
Figure 2
Pharmacodynamics of romiplostim. Mean platelet count‐time profiles (linear plot). The error bars are standard deviations.

References

    1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. New Engl J Med. 2002;346(13):995‐1008.
    1. Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol/Oncol Clin North Am. 2007;21(4):743‐759, vii.
    1. Al‐Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. Semin Thromb Hemost. 2020;46(3):275‐288.
    1. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence‐based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190‐4207.
    1. Cooper N, Ghanima W. Immune thrombocytopenia. New Engl J Med. 2019;381(10):945‐955.
    1. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829–2835.
    1. Feudjo‐Tepie MA, Robinson NJ, Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost. 2008;6(4):711–712.
    1. Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre‐Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population‐based study in France. Blood. 2014;124(22): 3308‐3315.
    1. Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population‐based study and literature review. Int J Hematol. 2011;93(3):329‐335.
    1. Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Brit J Haematol. 2009;145(2): 235‐244.
    1. Lee JY, Lee JH, Lee H, et al. Epidemiology and management of primary immune thrombocytopenia: a nationwide population‐based study in Korea. Thromb Res. 2017;155:86‐91.
    1. Fogarty PF. Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hematol/Oncol Clin North Am. 2009;23(6):1213‐1221.
    1. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second‐line treatment. Blood. 2012;120(5):960‐969.
    1. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780‐3817.
    1. Cooper N. State of the art ‐ how I manage immune thrombocytopenia. Brit J Haematol. 2017;177(1):39‐54.
    1. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004;79(4):504‐522.
    1. Keating GM. Romiplostim: a review of its use in immune thrombocytopenia. Drugs. 2012;72(3):415‐435.
    1. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double‐blind randomised controlled trial. Lancet (London, England). 2008;371(9610):395‐403.
    1. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. New Engl J Med. 2010;363(20):1889‐1899.
    1. Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double‐blind, randomized phase III clinical trial. Int J Hematol. 2011;94(1):71‐80.
    1. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Therap. 2004;76(6):628‐638.
    1. Kuter DJ. Milestones in understanding platelet production: a historical overview. Brit J Haematol. 2014;165(2):248‐258.
    1. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis‐stimulating protein, for chronic ITP. New Engl J Med. 2006;355(16):1672‐1681.
    1. Wang YM, Sloey B, Wong T, Khandelwal P, Melara R, Sun YN. Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism. Pharm Res. 2011;28(8):1931‐1938.
    1. Yang BB, Doshi S, Arkam K, Franklin J, Chow AT. Development of romiplostim for treatment of primary immune thrombocytopenia from a pharmacokinetic and pharmacodynamic perspective. Clin Pharmacokinet. 2016;55(9):1045‐1058.
    1. Chen F, McDonald V, Newland A. Experts’ review: the emerging roles of romiplostim in immune thrombocytopenia (ITP). Expert Opin Biol Ther. 2021;2021:1‐11.
    1. Lozano ML, Godeau B, Grainger J, et al. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Expert Rev Hematol. 2020;13(12):1319‐1332.
    1. Krzyzanski W, Sutjandra L, Perez‐Ruixo JJ, Sloey B, Chow AT, Wang YM. Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals. Pharm Res. 2013;30(3):655‐669.
    1. Arkam K, Doshi S, Yang BB. Pharmacokinetic and pharmacodynamic properties of romiplostim. Blood. 2014;124(21):1463.
    1. Cooper N, Terrinoni I, Newland A. The efficacy and safety of romiplostim in adult patients with chronic immune thrombocytopenia. Ther Adv Hematol. 2012;3(5):291‐298.
    1. Rodeghiero F, Stasi R, Giagounidis A, et al. Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol. 2013;91(5):423‐436.
    1. Kuter DJ, Arnold DM, Rodeghiero F, et al. Safety and efficacy of self‐administered romiplostim in patients with immune thrombocytopenia: results of an integrated database of five clinical trials. Am J Hematol. 2020;95(6):643‐651.
    1. Vishnu P, Aboulafia DM. Long‐term safety and efficacy of romiplostim for treatment of immune thrombocytopenia. J Blood Med. 2016;7:99‐106.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit